These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33776879)

  • 21. [A preliminary assessment of the clinical utility of measuring hepatitis C virus antibody to evaluate infection status].
    Long L; Liu Y; Duan Z; Xu Q; Shen T; Dou X; Zhuang H; Lu F
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):244-50. PubMed ID: 25173220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana.
    Boateng R; Mutocheluh M; Dompreh A; Obiri-Yeboah D; Odame Anto E; Owusu M; Narkwa PW
    PLoS One; 2019; 14(4):e0215377. PubMed ID: 31002687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
    Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
    J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients.
    Otegbayo JA; Taiwo BO; Akingbola TS; Odaibo GN; Adedapo KS; Penugonda S; Adewole IF; Olaleye DO; Murphy R; Kanki P
    Ann Hepatol; 2008; 7(2):152-6. PubMed ID: 18626434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
    Isakov V; Gankina N; Morozov V; Kersey K; Lu S; Osinusi A; Svarovskaia E; Brainard DM; Salupere R; Orlova-Morozova E; Zhdanov K
    Clin Drug Investig; 2018 Mar; 38(3):239-247. PubMed ID: 29177645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy.
    Farcomeni S; Moretti S; Fimiani C; Sulekova LF; Vescio F; Sernicola L; Maggiorella MT; Remoli AL; Picconi O; Mosca L; Esvan R; Biliotti E; Ciccozzi M; Sgarbanti M; Taliani G; Borsetti A
    Pathogens; 2021 Nov; 10(11):. PubMed ID: 34832642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study.
    Vassallo M; Dunais B; Durant J; Carsenti-Dellamonica H; Harvey-Langton A; Cottalorda J; Ticchioni M; Laffon M; Lebrun-Frenay C; Dellamonica P; Pradier C
    J Neurovirol; 2013 Aug; 19(4):376-82. PubMed ID: 23846287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
    Potter M; Odueyungbo A; Yang H; Saeed S; Klein MB;
    AIDS; 2010 Jul; 24(12):1857-65. PubMed ID: 20479633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive trajectories after treatment in acute HIV infection.
    Chan P; Kerr SJ; Kroon E; Colby D; Sacdalan C; Hellmuth J; Reiss P; Vasan S; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS; 2021 May; 35(6):883-888. PubMed ID: 33534200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults.
    Bharti AR; McCutchan A; Deutsch R; Smith DM; Ellis RJ; Cherner M; Woods SP; Heaton RK; Grant I; Letendre SL
    Clin Infect Dis; 2016 Dec; 63(12):1655-1660. PubMed ID: 27794019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demographic and clinical factors associated with immune reconstitution in HIV/HBV co-infected and HIV mono-infected patients: a retrospective cohort study.
    Jiang TY; Hou JH; Su B; Zhang T; Yang Y; Liu ZY; Wang W; Guo CP; Dai LL; Sun LJ; Wu H
    HIV Med; 2020 Dec; 21(11):722-728. PubMed ID: 33369028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.
    Tural C; Fuster D; Tor J; Ojanguren I; Sirera G; Ballesteros A; Lasanta JA; Planas R; Rey-Joly C; Clotet B
    J Viral Hepat; 2003 Mar; 10(2):118-25. PubMed ID: 12614468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda.
    Rusine J; Ondoa P; Asiimwe-Kateera B; Boer KR; Uwimana JM; Mukabayire O; Zaaijer H; Mugabekazi J; Reiss P; van de Wijgert JH
    PLoS One; 2013; 8(5):e63303. PubMed ID: 23717409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women.
    Richardson JL; Nowicki M; Danley K; Martin EM; Cohen MH; Gonzalez R; Vassileva J; Levine AM
    AIDS; 2005 Oct; 19(15):1659-67. PubMed ID: 16184036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients.
    He X; Hopkins L; Everett G; Carter WM; SchroppDyce C; Abusaada K; Hsu V
    World J Hepatol; 2017 Oct; 9(30):1190-1196. PubMed ID: 29109851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Doyle MA; Singer J; Lee T; Muir M; Cooper C
    Trials; 2016 Jul; 17(1):331. PubMed ID: 27439433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.